Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • University of Strathclyde

    - PMLiVE

    Scientists uncover new drug target in fight against antimicrobial resistance

    The discovery could lead to improved treatments for bacterial infections

    - PMLiVE

    Lilly and WHO Foundation partner to support global dementia action plan

    The partnership will provide financial support and strengthen early detection and intervention efforts

    - PMLiVE

    Lilly launches global Alzheimer’s campaign with Julianne Moore

    The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

    - PMLiVE

    TRIMTECH Therapeutics establishes Scientific Advisory Board

    Alessio Ciulli has been appointed as Chair of the board

    - PMLiVE

    Roche shares promising data from Alzheimer’s disease development portfolio

    The company is planning to initiate phase 3 studies of trontinemab in early AD this year

    - PMLiVE

    UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

    It is hoped that the test could be available for widespread UK use in the coming years

    - PMLiVE

    GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

    The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    - PMLiVE

    UK drug repurposing study identifies several potential dementia treatments

    An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

    - PMLiVE

    Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

    The neurodegenerative disease affects approximately 30,000 people in the US

    - PMLiVE

    Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

    The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links